Published in

Springer Nature [academic journals on nature.com], British Journal of Cancer, 2(76), p. 264-265, 1997

DOI: 10.1038/bjc.1997.373

Links

Tools

Export citation

Search in Google Scholar

Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.

Journal article published in 1997 by Woll Pj, Pj J. Woll ORCID, R. Basser, T. Le Chevalier, P. Drings, G. Perez Manga, A. Adenis, L. Seymour, F. Smith, Nick Thatcher
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Raltitrexed, a thymidylate synthase inhibitor, was given to 21 patients with advanced small-cell lung cancer, at a dose of 3 mg m(-2) as a 15-min intravenous infusion at 21-day intervals. All of the patients had extensive disease and 17 had received prior therapy. Patients with disease refractory to primary chemotherapy were excluded. Forty-one treatment cycles were given (median two, range one to four). The drug was well tolerated. No objective tumour response was documented. The patients had chemoresistant disease, as shown by a response in only one of ten patients who went on to receive alternative cytotoxic regimens. We conclude that raltitrexed given in this schedule is inactive as second line therapy for small-cell lung cancer.